Jan Münch

This inventor holds 7 USPTO granted patents and 2 published patent applications and 6 EPO patents. Top assignees: Ipf Pharmaceuticals Gmbh, Pharis Biotec Gmbh, Pharis Biotech Gmbh. Active years: 2006-2019.

USPTO Granted Patents = 7 (Patent Applications = 2)

% Patents Active = 57.1

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Erlangen, DE (2006)
Ulm, DE (2010 - 2012)
Neu-Ulm, DE (2014 - 2015)
Hannover, DE (2019)

Company Filing History:

3 out of 6

Ipf Pharmaceuticals Gmbh

Viro Pharmaceuticals Gmbh & Co. Kg

patent

5. 1 out of 834,453

Other

patents

Years Active: 2006-2019

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10294272 - Peptides with antagonistic activities against natural CXCR4 (2019-05-21),

2. 9045563 - CXC chemokine receptor 4 (CXCR4) antagonistic polypeptide (2015-06-02),

3. 8652483 - Viral infection enhancing peptide (2014-02-18),

4. 8299031 - Human semen enhancer of viral infection peptides (SEVI) and their use (2012-10-30),

5. 7741287 - Peptides for the treatment of herpes virus infections (2010-06-22),

6. 7655629 - Peptides and their use for the treatment of HIV infections (2010-02-02),

7. 7037896 - Peptide (VIRIP) which inhibits a circulating virus in humans and the use thereof (2006-05-02),

Title: Jan Münch: Innovator in Peptide Research

Introduction

Jan Münch is a prominent inventor based in Ulm, Germany. He has made significant contributions to the field of peptide research, particularly in the development of peptides with antagonistic activities against the CXCR4 receptor. His innovative work has led to the filing of several patents, showcasing his expertise and dedication to advancing medical science.

Latest Patents

Jan Münch holds 7 patents that reflect his groundbreaking research. His latest patents include a peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection, demonstrating an IC value of less than 50 µM. Another notable patent involves a CXC chemokine receptor 4 (CXCR4) antagonistic polypeptide, which encompasses a specific amino acid sequence and its biologically active fragments, variants, and derivatives. These innovations are crucial in the ongoing fight against HIV and related diseases.

Career Highlights

Throughout his career, Jan Münch has worked with notable companies such as Ipf Pharmaceuticals GmbH and Pharis Biotech GmbH. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in peptide technology.

Collaborations

Jan Münch has collaborated with esteemed colleagues, including Frank Kirchhoff and Wolf-Georg Forssmann. These partnerships have enriched his research and expanded the impact of his innovations in the scientific community.

Conclusion

Jan Münch is a distinguished inventor whose work in peptide research has led to important advancements in medical science. His patents and collaborations reflect his commitment to innovation and the betterment of healthcare.